Presentations & Publications
Access a wide range of resources that provide detailed information on our products, programs, and collaborations.
ASTX029 – Solid Tumors
2021
- 2021 EORTC: Treatment with the dual mechanism ERK inhibitor, ASTX029, alters myeloid cell differentiation
- Heightman et al., “Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2”
- Munck et al., “ASTX029, a Novel Dual-Mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK”
- 2021 AACR: A first-in-human, Phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors
- 2021 AACR: Immune modulation by the dual-mechanism ERK inhibitor, ASTX029, in MAPK-activated tumor models
2020
- 2020 ASH: Anti-tumor Activity of ASTX029, a Dual Mechanism Inhibitor of ERK1/2, in Preclinical AML Models
- Combined inhibition of SHP2 and ERK enhances anti-tumor effects in preclinical models
- The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 Inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models
2018
2017
2016
2015
Presentations & Publications Archive
© Astex Pharmaceuticals
All rights reserved
